TCBPY
TC Biopharm (Holdings) Plc0.1110
+0.0010+0.91%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
233.44KP/E (TTM)
-Basic EPS (TTM)
-128.32Dividend Yield
0%Recent Filings
8-K
Directors resign immediately
TC Biopharm (Holdings) PLC announced the immediate resignations of directors Mark Bonyhadi and Edward Niemzyck on June 26, 2024, with no disagreements cited over company operations, policies, or practices. This board shakeup leaves the leadership team leaner amid ongoing biotech challenges. No interim appointments disclosed.
8-K
Nasdaq equity compliance warning
TC Biopharm received Nasdaq notice on May 24, 2024, flagging noncompliance with the $2.5 million minimum stockholders' equity rule as of March 31, despite recent warrant exercises yielding ~$3.9 million in proceeds that restored compliance. Nasdaq warns of likely future breach by June 30 absent a major deal, triggering a mandatory panel monitor. The company plans a hearing to seek continued listing. Trading suspension is stayed until the panel decides.
8-K
Warrant exercise boosts equity
TC Biopharm secured £3.1 million ($3.9 million) in gross proceeds on May 8, 2024, from holders exercising 1,750,000 existing Series E warrants at $0.125 per ADS, in exchange for new Series F warrants covering 3,500,000 ADSs. This infusion addressed the company's prior noncompliance with Nasdaq's $2.5 million minimum stockholders' equity rule, as flagged in its Q1 10-Q filed May 15. Compliance restored. Yet, the new warrants introduce potential dilution risks.
10-Q
Q1 FY2024 results
TC Biopharm narrowed its Q1 operating loss to £3.4 million, down 17% year-over-year from £4.2 million, as research and development expenses dropped 33% to £1.3 million amid a clinical strategy refocus, while administrative costs edged 4% lower to £2.1 million despite higher share-based compensation. Net loss widened to £3.3 million from £0.6 million, driven by the prior year's one-time £3.1 million gain on derivative fair value changes; EPS came in at -£0.11 on 30.1 million diluted shares, reflecting anti-dilution from warrant exercises that boosted shares outstanding. Cash burn eased to £2.4 million in operations, with £1.0 million cash on hand after £0.9 million from Series D warrant exercises, but liquidity remains tight with a £0.6 million working capital deficit and no debt. Ongoing litigation over a converted £0.6 million loan note adds uncertainty, potentially dragging into late 2024.
8-K
Warrant exercise nets £3.1M
TC Biopharm secured warrant exercises from holders of its Series E warrants, issued December 2023 at £1.5814 per ADS, for 1,750,000 ADSs yielding £3.1 million gross proceeds before fees. In exchange, it issued new Series F warrants for 3,500,000 ADSs at £1.175 each, exercisable immediately for 42 months, closing May 8, 2024. Funds will fuel a relapse/refractory AML clinical trial and operations. Yet dilution looms large.
CBIO
Crescent Biopharma, Inc.
12.92-0.29
CERO
CERo Therapeutics Holdings, Inc
0.09-0.01
COEP
Coeptis Therapeutics Holdings,
14.43-0.66
CRBU
Caribou Biosciences, Inc.
1.69-0.02
ESLA
Estrella Immunopharma, Inc.
1.63-0.18
GDTC
CytoMed Therapeutics Limited
1.62+0.02
GTBP
GT Biopharma, Inc.
0.72+0.09
IMTX
Immatics N.V.
10.09+0.11
INAB
IN8bio, Inc.
1.50-0.10
MRKR
Marker Therapeutics, Inc.
1.27-0.12